West Pharma Q4 net sales $748.8M (+2.3%), adj EPS $1.82; FY25 guidance $6.00-$6.20 EPS

WEST PHARMACEUTICAL SERVICES INC

2024-FY EPS reported $6.69 revenue$2,893,200,000

Q4 organic net sales grew 3.3%, driven by Proprietary Products (+4.5%) led by self-injection devices.
FY 2025 guidance: net sales $2.875B-$2.905B; adjusted EPS $6.00-$6.20 (vs. FY24 $6.75).
Proprietary Products Q4 HVP sales were 74% of segment; Biologics unit had high-single-digit organic growth.
FY 2024 free cash flow $276.4M, down 33.3%; $560.9M spent on share repurchases during year.
CEO cited improving HVP trends in Biologics/Generics and growth from Annex 1 and GLP-1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.